pipette
ESEspañol

Loss of CDKN2A remodels Golgi morphology to create a lipid peroxidation vulnerability

A. Amalric, B. Yang, R. Scarpati, A. Uboveja, R. Zheng, A. Tom, A. R. Cole, A. A. Huacachino, Q. Liu, N. W. Snyder, A. V. Kossenkov, K. M. Aird, R. Buj

Preprint

In the authors' words

Loss of the tumor suppressor CDKN2A/p16 occurs in ~50% of human cancers, yet no therapies specifically target tumors with complete loss or reduced CDKN2A/p16 expression (hereafter CDKN2A/p16-Low). Identifying selective vulnerabilities in CDKN2A/p16-Low tumors therefore represents a critical unmet need. Here, we identify altered Golgi morphology as a vulnerability in CDKN2A/p16-Low melanoma. A CRISPR knockout screen revealed that genes associated with Golgi membranes are essential for CDKN2A/p16-Low cell survival. CDKN2A/p16 knockdown in human and murine cancer cells was associated with striking Golgi compaction. CDKN2A/p16 knockdown sensitized cells to pharmacologic Golgi disruption via lipid peroxidation both in vitro and in vivo. Notably, reduced Retinoblastoma-associated protein (RB1) expression did not recapitulate the increased sensitivity to Golgi disruption, supporting a role for non-canonical p16 functions in this vulnerability. Together, these findings uncover a previously unrecognized link between CDKN2A/p16-Low status and Golgi remodeling, revealing a Golgi-associated metabolic vulnerability in CDKN2A/p16-Low melanomas.

Main resultThe abstract does not state a limitation.

Appeared: Friday, November 13. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.10.765755